Table 2.
Logistic regression models for the risk of 24-h and daytime BP control (n = 520)
| Variable | 24-h BP control | Daytime BP control | ||
|---|---|---|---|---|
| Model 1 | Model 2 | Model 1 | Model 2 | |
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| Age (years) | 1.0 (0.9–1.0) | 1.0 (1.0–1.1) | 1.0 (0.9–1.0) | 1.0 (1.0–1.1) |
| Sex (ref. female) | 0.8 (0.5–1.1) | 0.8 (0.5–1.1) | 0.9 (0.6–1.3) | 0.9 (0.6–1.3) |
| BMI (kg/m2) | 1.0 (0.9–1.1) | 1.0 (1.0–1.1) | 1.0 (1.0–1.1) | 1.0 (1.0–1.1) |
| Smoking habit | 0.9 (0.7–1.3) | 0.9 (0.7–1.4) | 0.9 (0.6–1.3) | 0.9 (0.6–1.3) |
| T2DM | 1.0 (0.7–1.5) | 1.0 (0.7–1.5) | 0.8 (0.5–1.2) | 0.8 (0.5–1.2) |
| eGFR (ml/min/1.73 m2) | 1.0 (0.9–1.0) | 1.0 (1.0–1.1) | 1.0 (0.9–1.0) | 1.0 (1.0–1.1) |
| ACEi-based triple therapy vs ARB-based triple therapy (ref. ARB-based triple therapy) | 1.5 (1.1–2.2)* | 1.2 (0.8–1.9) | 1.6 (1.1–2.4)* | 1.4 (0.9–2.1) |
| ATI | 1.0 (0.6–1.6) | – | 0.8 (0.5–1.3) | – |
| Number of antihypertensive pills (ref. 1) | ||||
| 1 | – | – | ||
| 2 | 0.5 (0.2–1.0)* | 0.4 (0.2–0.9)* | ||
| 3 | 0.2 (0.1–0.7)* | 0.4 (0.1–1.1) | ||
BP blood pressure, OR odds ratio, CI confidence interval, BMI body mass index, T2DM type 2 diabetes mellitus, eGFR estimated glomerular filtration rate, ATI antihypertensive treatment intensity
*p < 0.05, **p < 0.001
Model 1 included age, sex, BMI, smoking habit, T2DM, eGFR, ATI as covariates
Model 2 included all model 1 variables except ATI, which was substituted by number of antihypertensive pills, as covariates